HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
D4054 Glembatumumab vedotin Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma. Jun 30 2023
D4055 Loncastuximab tesirine Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG. Jun 30 2023
D4057 Ladiratuzumab vedotin Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas. Jun 30 2023
D4042 Depatuxizumab mafodotin Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM). Jun 29 2023
E2964 Norepinephrine tartrate Norepinephrine tartrate is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. Jun 28 2023
E2950 Fat Emulsion（20%） Fat Emulsion（20%）is a safe fat emulsion that can be used as a nutritional supplement. Fat Emulsion（20%）inhibits the opening of the mitochondrial permeability transition pore and effectively protecting the heart from ischaemia-reperfusion injury. It has some potential to modulate the innate immune response. Jun 28 2023
E1217 PCLX-001 (DDD86481) PCLX-001 (DDD86481) is an orally active dual N-myristoyltransferase (NMT) inhibitor. It inhibits NMT1 and NMT2 with IC50 of 5 nM and 8 nM, respectively, in vitro. PCLX-001 inhibits early B-cell receptor (BCR) signalling, which can be used in B-cell malignancy research. Jun 28 2023
E2969 Mannan Mannan is one of the major components of the yeast cell wall. It can be used to coat the microtiter wells to quantify the levels of mannose-binding lectin (MBL) using a mannan-binding enzyme-linked immunosorbent assay (ELISA). Mannan exhibits antiproliferative, antioxidant, and immunomodulatory properties. Jun 28 2023
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. Jun 28 2023
D4026 Tusamitamab ravtansine Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. Jun 27 2023
D4027 Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands. Jun 27 2023
D4030 Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. Jun 27 2023
D4031 Cantuzumab mertansine Cantuzumab mertansine (HUC242-DM1, SB-408075) is an anti-MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242), humanized monoclonal antibody conjugated to maytansinoid DM1 ([N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine]) via a reductible SPP linker [N-succinimidyl 4-(2-pyridyldithio)pentanoate]. Jun 27 2023
D4032 Cantuzumab ravtansine Cantuzumab ravtansine (IMGN242, HUC242-DM4) is an ADC. It is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. Jun 27 2023
D4033 Ozuriftamab vedotin Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Jun 27 2023
D4034 Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). Jun 27 2023
D4036 Sofituzumab vedotin Sofituzumab Vedotin (DMUC5754A, RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker. DMUC5754A binds to the MUC16 extracellular domain with high affinity. Jun 27 2023
D4037 Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond. Jun 27 2023
D4038 Enapotamab vedotin Enapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker. Jun 27 2023
D4039 Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. Jun 27 2023